48P Surveillance strategy is safe in stage I dysgerminomas: results from the MITO-9

ESMO rare cancers. 2026 Open access

Read full text
Authors: Maria Vittoria Luciani, Robert Fruscio, Gennaro Cormio, A. Fagotti, Saverio Danese, Chiara Cassani, F. Perrone, D. Giuliani, Giovanna Scarfone, Emanuele Naglieri, Michele Bartoletti, Sandro Pignata
+2 more Giorgia Mangili, Alice Bergamini
DOI: 10.1016/j.esmorc.2026.100254
Cited by: 0

Abstract

The management of stage I dysgerminomas is for many aspects controversial according to European guidelines. Only few data are available in literature specifically addressing the role of adjuvant chemotherapy (ADJCT) in this setting, especially for stage IC. Here, we investigate this aspect in the largest available series deriving from a multicenter collaboration within the MITO group (Multicenter Italian Trials in Ovarian Cancer).

Fields of Study & Subjects

Ovarian cancer diagnosis and treatment Endometrial and Cervical Cancer Treatments BRCA gene mutations in cancer

Publication details

Journal / source
ESMO rare cancers.
Volume
5
Pages
100254–100254
Publication date
1 March 2026
Language
EN